ClinicalTrials.gg
RecruitingNCT05144516Updated Feb 10, 2026

Cancer and Mild Cognitive Impairment Dyadic Intervention

An interventional study of Behavioral: COPE + in Cancer and Cognitive Impairment, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Duke University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The purpose of this study is to see whether programs that include both a patient and their spouse or a patient and family caregiver (known as a dyad) are helpful for families in which one member of the dyad has cancer and mild memory difficulties and/or concerns. Participant and their spouse or participant and their family caregiver will have six, 60-minute video-conference sessions which will be scheduled at their convenience. The investigator will loan participants a tablet computer (iPad) to use for videoconferencing and train the participant in its use. Participant and their spouse or participant and their family caregiver will complete three assessments - one before starting the sessions, one after the sixth session, and one after 1 month. Each assessment will include surveys, which the participant will complete separately from their spouse or family caregiver. For most people, it will take upwards of 2 - 4 months to complete this study

02

Conditions studied

  • Cancer
  • Cognitive Impairment

Keywords

  • Aging
  • Behavioral Intervention
  • Mental Health
  • Communication
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Patient inclusion criteria include:

  1. Patients with Stage I-IV breast, gastrointestinal (GI), genitourinary (GU), or lung cancer (including extensive stage small cell lung cancer), diagnosed within two years; age 65 or older.
  2. Participants must be living at home (either in her/his own home).
  3. Participants must be fluent in English and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions.
  4. Exhibit Mild Cognitive Impairment/Concerns
  5. Have an informal family caregiver.

Inclusion Criteria:

(Partner or family member) inclusion criteria include:

  1. Caregivers are 18 older.
  2. Be fluent in English and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions.
  3. Either co-reside with the patient or spend at least 3-4 hours day caregiving.
  4. Not exhibit cognitive impairment.

Exclusion Criteria:

  1. Participant has visual or hearing impairments that preclude participation.
  2. Participant has dementia and do not have the capacity to participate.
  3. Have a serious untreated psychiatric illness as documented in medical chart review.
  4. The patient and the caregiver score less than a 3 on the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) on a scale 0 to 10 to screen for distress. At least one dyad member must experience distress.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Patient Caregiver Dyad

    Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.

    Behavioral: Behavioral: COPE +

Interventions

  • BehavioralBehavioral: COPE +

    Six sixty minute sessions that teaches participants distress and communication coping skills.

06

What researchers measure

Primary outcomes

  1. Number of completed sessions as measured by enrollment log

    Time frame: Up to 17 Weeks

  2. Number of participants who are satisfied with the intervention as measured by a score of 24 or greater on the CSQ-8

    The Client Satisfaction Questionnaire (CSQ-8) is a self report measure of satisfaction with health and behavioral services received. The CSQ-8 is measured on a four point Likert scale from 1 "Quite Dissatisfied" to 4 "Very Satisfied." Scores range from 8-32, with higher values indicating higher satisfaction

    Time frame: Up to 17 weeks

Secondary outcomes

  1. Change in Distress as measured by the DASS-21

    The Depression, Anxiety, and Stress Scale (DASS-21) measure will be used for rating general distress across three emotional states of depression, anxiety, and stress. The measure has a total of 21 items. Scores range from 0- 63, with higher scores indicating greater distress.

    Time frame: Baseline, up to 17 weeks, up to 1 month follow up

  2. Change in Quality of Life as measured by the FACT-G

    The Functional Assessment of Cancer Therapy: General (FACT-G) measure will be used for rating quality of life. The measure has a total of 27 items. Scores range from 0-108, with higher scores indicating greater quality of life.

    Time frame: Baseline, up to 17 weeks, up to 1 month follow up

  3. Change in Communication Patterns as measured by the CPQ-SF

    The Communication Patterns Questionnaire Short-Form (CPQ-SF) will be used for rating communication patterns in a relationship. The measure has a total of 11 items. Scores range from 11-99, higher scores indicate a greater likelihood of using a particular communication pattern during conflict interactions.

    Time frame: Baseline, up to 17 weeks, up to 1 month follow up

  4. Change in Relationship Satisfaction as measured by the Mutuality Scale of the Family Care Inventory

    The Mutuality Scale of the Family Care Inventory will be used for rating mutual concerns and overall relationship satisfaction. The measure consists of 15 items. Scores range from 0-60, higher scores indicate greater relationship satisfaction

    Time frame: Baseline, up to 17 weeks, up to 1 month follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Aug 2027, 35 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 35 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Dec 3, 2021
StartActual
Sep 30, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05144516
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
Sep 30, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Katherine Ramos, Ph.D.
Contact
Katherine.Ramos@duke.edu
9194163434
Kaylee Faircloth
Contact
Kaylee.Faircloth@duke.edu
9194163479
Katherine Ramos, Ph.D.
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion